High-grade astrocytomas: Resource use, clinical outcomes, and cost of care

被引:0
|
作者
Silverstein, MD
Cascino, TL
Harmsen, WS
机构
[1] MAYO CLIN & MAYO FDN,DEPT NEUROL,CLIN EPIDEMIOL SECT,ROCHESTER,MN 55905
[2] MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To describe the clinical course, survival, resource use, and direct medical costs of care for patients with high-grade astrocytomas. Material and Methods: All patients with grade 3 or 4 astrocytoma who resided in Olmsted County, Minnesota, or one of the six adjacent counties and had a tissue diagnosis first made between 1987 and 1992 were studied. Clinical characteristics, initial management, use of resources, clinical course, survival, and medical charges were analyzed. Results: Sixty-four patients, with a mean age of 62 years, were identified; 81% had glioblastoma multiforme. Approximately 60% underwent surgical resection, 80% had radiotherapy, and 50% had chemotherapy for initial management. After initial treatment (median duration, 116 days), approximately 75% of patients had a course with stable disease (median duration, 198 days), The overall median duration of survival was 323 days; lower grade and younger age were significantly associated with longer median survival-for example, 1,493 days for patients younger than 65 years with grade 3 astrocytomas and 205 days for patients 65 gears old or older with grade 4 astrocytomas. The mean total direct medical charges were $67,887. Conclusion: In most patients with high-grade astrocytomas, a substantial period elapsed before disease progressed. Although the overall median duration of survival was less than I year, younger patients, especially those with grade 3 astrocytomas, had a longer survival. The management of patients with high-grade astrocytomas uses substantial health-care resources.
引用
收藏
页码:936 / 944
页数:9
相关论文
共 50 条
  • [21] Increased expression of 5-lipoxygenase in high-grade astrocytomas
    Nathoo, N
    Prayson, RA
    Bondar, J
    Vargo, L
    Arrigain, S
    Mascha, EJ
    Suh, JH
    Barnett, GH
    Golubic, M
    NEUROSURGERY, 2006, 58 (02) : 347 - 353
  • [22] THE MONONUCLEAR CELL INFILTRATE COMPARED WITH SURVIVAL IN HIGH-GRADE ASTROCYTOMAS
    ROSSI, ML
    JONES, NR
    CANDY, E
    NICOLL, JAR
    COMPTON, JS
    HUGHES, JT
    ESIRI, MM
    MOSS, TH
    CRUZSANCHEZ, FF
    COAKHAM, HB
    ACTA NEUROPATHOLOGICA, 1989, 78 (02) : 189 - 193
  • [23] Continuous hyperfractionated accelerated radiotherapy in the treatment of high-grade astrocytomas
    Bese, NS
    Uzel, Ö
    Turkan, S
    Okkan, S
    RADIOTHERAPY AND ONCOLOGY, 1998, 47 (02) : 197 - 200
  • [24] CONCERNS ABOUT ANGIOGENESIS INHIBITION AS TREATMENT FOR HIGH-GRADE ASTROCYTOMAS
    Verhoeff, Joost
    Van Tellingen, Olaf
    Claes, An
    Stalpers, Lukas
    Van Linde, Myra
    Richel, Dick
    Leenders, William
    Van Furth, Wouter
    NEURO-ONCOLOGY, 2008, 10 (05) : 861 - 861
  • [25] MR of recurrent high-grade astrocytomas after intralesional immunotherapy
    Smith, MM
    Thompson, JE
    Castillo, M
    Cush, S
    Mukherji, SK
    Miller, CH
    Quattrocchi, KB
    AMERICAN JOURNAL OF NEURORADIOLOGY, 1996, 17 (06) : 1065 - 1071
  • [26] High-grade intramedullary astrocytomas: what is the best surgical option?
    Fehlings, Michael G.
    Craciunas, Sorin C.
    JOURNAL OF NEUROSURGERY-SPINE, 2010, 12 (02) : 141 - 142
  • [27] Potential Canonical Wnt Pathway Activation in High-Grade Astrocytomas
    Schuele, Rebecca
    Dictus, Christine
    Campos, Benito
    Wan, Feng
    Felsberg, Joerg
    Ahmadi, Rezvan
    Centner, Franz-Simon
    Grabe, Niels
    Reifenberger, Guido
    Bermejo, Justo L.
    Unterberg, Andreas
    Herold-Mende, Christel
    SCIENTIFIC WORLD JOURNAL, 2012,
  • [28] LONG-TERM SURVIVORS OF HIGH-GRADE MALIGNANT ASTROCYTOMAS
    DARA, P
    SLATER, LM
    TALREJA, D
    ARMENTROUT, SA
    MEDICAL AND PEDIATRIC ONCOLOGY, 1980, 8 (02): : 187 - 191
  • [29] Targeting the Epidermal Growth Factor Receptor in High-Grade Astrocytomas
    Voelzke, Will R.
    Petty, W. Jeffery
    Lesser, Glenn J.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2008, 9 (01) : 23 - 31
  • [30] The molecular oncology of bilateral high-grade thalamic astrocytomas in children
    Amir Goodarzi
    Nicholas Garza
    Mirna Lechpammer
    Reuben Anthony
    Marike Zwienenberg
    Child's Nervous System, 2019, 35 : 2047 - 2054